EUVIMEDEUVIMED entdecken
Crossref

Xiebai San alleviates acute lung injury by inhibiting the phosphorylation of the ERK/Stat3 pathway and regulating multiple metabolisms

Anyi Zhao, Cong Guo, Lianmei Wang, Sha Chen, Qingxia Xu, Jintang Cheng, Jun Zhang, Jinzhu Jiang, Jipeng Di, Heng Zhang, Fangfang Chen, Jiangmin Su und 4 weitere

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2024.155397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Anyi Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese…. Hauptthemen laut MEDLINE: Acute Lung Injury, STAT3 Transcription Factor, Drugs, Chinese Herbal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Academy of Chinese Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute lung injury (ALI) often leads to serious respiratory diseases with high incidence rates and mortality. For centuries, Xiebai San (XBS) has been a classical traditional Chinese medicine (TCM) about respiratory illness such as pneumonia in children. However, the related mechanism of XBS against ALI remains indistinct. PURPOSE: To reveal specific targets of XBS in lipopolysaccharide (LPS)-induced ALI mice using integrated pharmacology. STUDY DESIGN: The integrated method was to expound mechanism and targets of XBS inhibited ALI. METHODS: The primary components in XBS were identified by ultra high performance liquid chromatography-quadrupole time of flight-mass spectrometry (UHPLC-QTOF-MS). The potential drug targets were established using network pharmacology. The anti-ALI effect of XBS was evaluated in mice. Additionally, therapeutic targets were screened by integrating metabolome and transcriptome and verified in lung tissue. RESULTS: In total, 163 chemical components were identified in XBS, and a network of "3 drugs-18 components-86 targets" for XBS against ALI was constructed. In ALI mice, XBS alleviated lung inflammation by decreasing permeation and expression of neutrophils, tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in bronchoalveolar lavage fluid (BALF), serum, and lung tissue. Next, the transcriptome of lung tissue was analyzed and enriched, indicating the importance of mitogen-activated protein kinase (MAPK), Janus kinase-signal transducer and activator of transcription (JAK-STAT), and others, which was consistent with network pharmacology prediction. Also, western blotting and immunohistochemistry results showed that XBS was against ALI mainly by inhibiting extracellular signal regulated kinase (ERK) and signal transducer and activator of transcription 3 (Stat3) phosphorylation. In addition, the metabolome of lung tissue revealed that XBS mainly regulated pathways involved in arachidonic acid, glycerophospholipid, and tryptophan metabolisms. The expression levels of leukotriene, phosphatidylcholine, kynurenine, and others were also verified. CONCLUSION: XBS alleviated inflammation of ALI by inhibiting the phosphorylation of the ERK/Stat3 pathway and regulating arachidonic acid, glycerophospholipid, and tryptophan metabolisms. This study will guide clinical precision medicine and promote modernization of XBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjurySTAT3 Transcription FactorDrugs, Chinese HerbalAnimalsMiceMalePhosphorylationLipopolysaccharidesMAP Kinase Signaling SystemLungMice, Inbred C57BLDisease Models, AnimalNetwork PharmacologySignal Transduction

Stichwörter der Autor:innen

Acute lung injuryMetabolomeNetwork pharmacologyTranscriptomeXiebai San

Substanzen

STAT3 Transcription FactorDrugs, Chinese HerbalLipopolysaccharidesStat3 protein, mouse

Autor:innen und Institutionen

  • Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Shandong Xianhe Pharmaceutical Co., Ltd, Dongying, Shandong 257237, China.
  • Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: yliu1980…
  • Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: aliu@icm…

Förderung

  • National Natural Science Foundation of China
  • China Academy of Chinese Medical Sciences

Zitieren

APA

Zhao, A., Guo, C., Wang, L., Chen, S., Xu, Q., Cheng, J., Zhang, J., Jiang, J., Di, J., Zhang, H., Chen, F., Su, J., Jiang, L., Liu, L., Liu, Y., & Liu, A. (2024). Xiebai San alleviates acute lung injury by inhibiting the phosphorylation of the ERK/Stat3 pathway and regulating multiple metabolisms. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155397

Vancouver

Zhao A, Guo C, Wang L, Chen S, Xu Q, Cheng J, et al. Xiebai San alleviates acute lung injury by inhibiting the phosphorylation of the ERK/Stat3 pathway and regulating multiple metabolisms. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.155397

BibTeX
@article{Zhao2024,
  author = {Zhao, Anyi and Guo, Cong and Wang, Lianmei and Chen, Sha and Xu, Qingxia and Cheng, Jintang and Zhang, Jun and Jiang, Jinzhu and Di, Jipeng and Zhang, Heng and Chen, Fangfang and Su, Jiangmin and Jiang, Liang and Liu, Li and Liu, Yan and Liu, An},
  title = {Xiebai San alleviates acute lung injury by inhibiting the phosphorylation of the ERK/Stat3 pathway and regulating multiple metabolisms},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2024.155397}
}
Kostenlos starten →